Advanced Medical Solutions Grp PLC Appointment of Chief Technology Officer (5277G)
27 Luglio 2021 - 8:00AM
UK Regulatory
TIDMAMS
RNS Number : 5277G
Advanced Medical Solutions Grp PLC
27 July 2021
27 July 2021
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Appointment of Chief Technology Officer
AMS strengthens its senior leadership team with appointment of
industry leader Chris Locke to newly created role of Chief
Technology Officer
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the surgical and advanced wound care specialist company , is
pleased to announce that on 9 August, Chris Locke will join the
Group's senior management team as Chief Technology Officer.
In this role Chris will take full responsibility for all
innovation, research, development and technology assessments for
the Group. He will be responsible for delivering the increasing
pipeline of high value innovation projects within our expanding
portfolio, as well as identifying external technology opportunities
complementary to the business.
Chris joins AMS from Acelity, having spent 20 years as a senior
manager within the $1.6 billion global KCI franchise, where he was
instrumental in the development, creation and launch of their
world-leading NPWT therapy range and other wound-care &
surgical technologies. Most recently he was Acelity's Chief
Innovation Officer and prior to that held roles as Vice President,
Research & Technology, Senior Director Global Innovation &
Strategic Marketing, and Director, Engineering, Design &
Technology. Chris is the named inventor on more than 500 US patent
applications and 329 granted US patents.
Chris Meredith, Chief Executive Officer of Advanced Medical
Solutions , said: "I am delighted to welcome Chris to the senior
management team. He brings a wealth of experience which will help
to drive further process improvement and delivery success from our
growing and innovative product portfolio."
Chris Locke, incoming Chief Technology Officer of Advanced
Medical Solutions , said: "I am very pleased to be joining AMS. I
look forward to contributing to the Company's continued growth as
we deliver quality outcomes for patients through innovative
surgical and woundcare products."
- Ends -
For further information, please contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Matthew AMS@consilium-comms.com
Cole
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Daniel Adams / Gary Clarence / Patrick
Robb
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. In 2019, the Group made two acquisitions: Sealantis,
an Israeli medical device company with a patent-protected sealant
technology platform; and Biomatlante, an established developer and
manufacturer of innovative surgical biomaterial technologies based
in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a
leading coater and converter of materials predominately for
woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has more than 700 employees. For more information, please see
www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAFXKAAXFEAA
(END) Dow Jones Newswires
July 27, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Advanced Medical Solutions (AQSE:AMS.GB)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Advanced Medical Solutions (AQSE:AMS.GB)
Storico
Da Mag 2023 a Mag 2024
